MAZE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Maze Therapeutics Inc (MAZE) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are neutral, options data suggests a lack of strong bullish sentiment, and the company's financial performance shows significant challenges with no revenue and negative income. While analysts have raised price targets and maintain a Buy rating, the lack of recent news or significant positive catalysts makes this stock a hold for now.
The MACD histogram is negative and expanding (-0.248), indicating bearish momentum. RSI is neutral at 47.308, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level (45.34), with resistance at 47.055 and support at 43.624.
The upcoming MZE-829 data and HORIZON data in APOL1-mediated kidney disease are potential catalysts.
The company's financials are weak, with no revenue and significant losses. Technical indicators do not show a strong bullish trend. There is no recent news or significant trading activity from insiders, hedge funds, or Congress.
In 2025/Q3, the company reported zero revenue (-100% YoY), a net income of -$30.087M (up 1139.68% YoY), and EPS of -0.66 (up 1000% YoY). Gross margin dropped to 0 (-100% YoY). The financials indicate significant challenges in profitability and growth.
Analysts maintain a Buy rating and have raised price targets multiple times, with the latest target at $58. They are optimistic about the upcoming data releases and see favorable risk/reward dynamics despite recent stock outperformance.
